CBO Still Weighing IRA’s Effect On Drug Innovation, Economic Outlook Omitted Issue

By Gabrielle Wanneh / February 9, 2024 at 4:26 PM
The Congressional Budget Office is continuing to assess new data on the Inflation Reduction Act’s impact on pharmaceutical innovation after its latest 10-year economic outlook looked at projections for the IRA’s clean vehicle and energy-related tax credits but not its drug price controls. CBO staff told Inside Drug Pricing the agency continues to receive and evaluate new research on drug innovation and how changes drug companies are expected to see in their future profits due to policies like drug...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.